Of note, treatment with IFNβ, glatiramer acetate, mycophenolate mofetil, natalizumab, alemtuzumab, and anti-CD20 agents is effective in the management of both MS and IU [12]. This evidence concerns the gene IFNB1 and myeloid sarcoma.